For optimal viewing of the AACI Update click here.
News from the Association of American Cancer InstitutesOctober 2015
The Association is dedicated to reducing the burden of cancer by enhancing the impact of the nation's leading academic cancer centers.
AACI Update is an e-newsletter for the cancer center directors and key contacts at AACI member institutions and individuals interested in the cancer center-related activities of AACI. AACI Update reports on the progress of AACI initiatives and other AACI endeavors that benefit the cancer community and highlights important news and events at AACI member institutions.

AACI encourages member institutions to submit cancer center highlights to AACI Update. News briefs are linked to complete stories posted on individual cancer center websites. Please e-mail materials to aaciupdate@aaci-cancer.org. AACI reserves the right to decide whether or not materials are appropriate for inclusion.

To subscribe to AACI Update, please send an e-mail to aaciupdate@aaci-cancer.org with your name, title, address, and telephone number asking to be added to the AACI's distribution list.

To unsubscribe from AACI Update, please send an e-mail to aaciupdate@aaci-cancer.org with your name, title, and unsubscribe in the subject line to be removed from AACI's distribution list.


Mailing address:
3708 Fifth Avenue
Medical Arts Building, 503
Pittsburgh, PA 15213

Headlines

Lewis Cantley to Receive 2015 AACI Distinguished Scientist Award
The Association of American Cancer Institutes will present the AACI Distinguished Scientist Award to Lewis Cantley, PhD, on October 26, during the 2015 AACI/CCAF Annual Meeting, in Washington, DC. Prior to the award presentation, Dr. Cantley will deliver a talk entitled, "Targeting PI3K for Cancer Therapy".

A cell biologist and biochemist who serves as The Margaret and Herman Sokol Professor in Oncology Research and director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, Dr. Cantley's pioneering research has resulted in revolutionary treatments for cancer, diabetes and autoimmune diseases. Among his research contributions was the discovery of the phosphoinositide 3-kinase (PI3K) pathway, which enabled a new understanding of the way biochemical signaling pathways control normal cell growth and how they can trigger the development of cancer when they are defective. more...


AACI to Honor Members of Congress at Annual Meeting
Sen. Patty Murray (D-WA) and Rep. Kevin Yoder (R-KS) will receive the 2015 AACI Public Service Award on October 26, in Washington, DC, during the AACI/CCAF Annual Meeting. Rep. Fred Upton (R-MI) and Rep. Diana DeGette (D-CO) also will be recognized for their efforts on H.R. 6, the 21st Century Cures Act. AACI's Board of Directors, the Annual Meeting Program Committee and the AACI Government Relations Forum Steering Committee selected the four members of Congress for recognition. more...

AACI CRI Announces New Steering Committee Chair
Paul J. Martin, MD has been appointed the new chair of the AACI Clinical Research Initiative (CRI) Steering Committee. Dr. Martin is director of the long-term follow-up program and medical director of clinical research support at the Fred Hutchinson Cancer Research Center, in Seattle. He has served on the AACI CRI Steering Committee since November 2013 and his two-year term as chair began September 1.

AACI also welcomes three new CRI steering committee members: Rosemarie Gagliardi, Tisch Cancer Institute, Mount Sinai Medical Center; Jessica Moehle, BS, CCRP, Huntsman Cancer Institute, University of Utah; and Steve Williamson, MD, University of Kansas Cancer Center. Read more about them at the AACI CancerBlog. more...

News from the Centers
Awards & Honors
Arteaga Lauded for Cancer Research Contributions
Vanderbilt-Ingram Cancer Center
Carlos L. Arteaga, MD, the Donna S. Hall Professor of Breast Cancer and director of the Center for Cancer Targeted Therapies and the Breast Cancer Program at Vanderbilt-Ingram Cancer Center, has been recognized for his cancer research efforts by the American-Italian Cancer Foundation. more...
Schreiber, Greenberg Named New Editors-in-chief of Cancer Immunology Research
American Association for Cancer Research (AACR)
The American Association for Cancer Research (AACR) recently announced the appointment of Robert D. Schreiber, PhD, and Philip D. Greenberg, MD, as editors-in-chief of Cancer Immunology Research, one of eight peer-reviewed journals published by the AACR. In their roles, Drs. Schreiber and Greenberg will set goals and determine editorial strategy for the journal. more...
Ohio State Earns National Pancreas Foundation Center Designation
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital & Solove Research Institute

The Ohio State University Wexner Medical Center, along with the James Cancer Hospital and Solove Research Institute, has been nationally recognized among only 30 hospitals in the United States to earn designation as a Pancreas Center of Excellence by the National Pancreas Foundation. more...
Grants & Gifts
Major Grant Application Earns NCI's Highest Recognition
UNC Lineberger Comprehensive Cancer Center
The UNC Lineberger Comprehensive Cancer Center earned an "exceptional" rating from the National Cancer Institute for a major grant application associated with the center's multidisciplinary research. The rating was given to UNC Lineberger's application to the NCI for renewal of a five-year grant that supports multidisciplinary research and shared scientific core resources for hundreds of scientists and clinicians in addition to other key center functions. The rating is the highest that a cancer center can earn for the application. more...
Strong Scores Put VICC Among Top NCI Centers
Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center (VICC) has been recognized for the impact of its research programs and excellence in patient care by a panel of National Cancer Institute (NCI) reviewers, receiving an overall "exceptional" score as part of the renewal of the Cancer Center Support Grant (CCSG). High programmatic scores and the overall merit rating led to another successful renewal of the NCI-CCSG grant for the center, providing almost $30 million over five years to support scientific leadership and administration, as well as infrastructure that includes shared resources for cancer investigators. more...
Funding Renewed for San Diego Universities, Community Health Centers to Work Together
UC San Diego Moores Cancer Center
A collaborative program aimed at reducing the burden of cancer among Hispanic/Latinos in San Diego and Imperial counties through research and community outreach has received a $13 million grant from the National Cancer Institute (NCI). The five-year grant renews funding for a partnership started in 2008 between San Diego State University and Moores Cancer Center at UC San Diego Health. Maria Elena Martinez, PhD is Moores' principal investigator on the partnership. more...
Researchers Receive NCI Outstanding Investigator Award
UC San Diego Moores Cancer Center
​Four University of California, San Diego School of Medicine researchers have been selected to receive the newly established National Cancer Institute (NCI) Outstanding Investigator Award. The recipients are Kun-Liang Guan, PhD, who will receive $5.9 million for his work with mTORC1 and Hippo pathways in cell growth and cancer; Tannishtha Reya, PhD, who was awarded $6.3 million for her project on molecular strategies for early detection and targeting of cancer; and Jin Zhang, PhD, who will receive $6.5 million to evaluate live-cell activity architecture in cancer. The funding amount for Michael Karin, PhD, is pending. Dr. Karin is studying the role of immunosuppressive B cells in the development of cancer and its treatment. more...
NCI Outstanding Investigator Awards for UT Southwestern Total $11.7 Million
Simmons Cancer Center, UT Southwestern Medical Center
The National Cancer Institute (NCI) has awarded two researchers at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center more than $11 million to support their exceptional research programs. Michael White, PhD, who studies personalized cancer therapies, and Dr. Joshua Mendell, MD, PhD, who studies biology mechanisms involved in cancer, received the awards. more...
Stanford Lands NCI Outstanding Investigator Awards
Stanford Cancer Institute
Three Stanford Cancer Institute members have garnered NCI Outstanding Investigator Awards, a new grant program to enable investigators to continue or embark upon new projects of unusual potential in cancer research over a period of seven years. The awardees are: Amato Giaccia, PhD, for his project, "The Impact of Mitochondrial Repression and Lipid Accumulation by HIF on Tumor Growth"; Steve Artandi, MD, PhD, for his project, "Reversing Cellular Immortality in Cancer"; and, Laura Attardi, PhD, for her project, "Integrative Approaches to Elucidate p53 Transcriptional Networks During Carcinogenesis". more...
Scientists to Lead $12 Million Initiative for New Treatments for Inherited Cancers
Indiana University Melvin and Bren Simon Cancer Center
The Indiana University School of Medicine has been selected to lead a five-year, $12 million national research project to develop new treatments for diseases of a genetic mutation that leads to disfiguring and life-threatening tumors and other developmental disorders, mainly in children. The grant, one of the highly competitive and coveted projects funded by the National Cancer Institute's Specialized Programs of Research Excellence initiative, is the first such SPORE grant to focus on pediatric cancers. D. Wade Clapp, MD, will serve as the corresponding principal investigator for the new project. more...
Childhood Cancer Research to Transcend Tissue Types With Innovative Grant
UCSF Helen Diller Family Comprehensive Cancer Center
Researchers at UC San Francisco are leading a five-year, $10 million research project dedicated to pediatric cancer, funded by the first grant of its kind to focus on a molecular pathway that underlies many cancers rather than on a cancer in a particular organ or tissue in the body. The new grant was awarded under the Specialized Programs of Research Excellence program of the National Cancer Institute. more...
Could Aspirin Treat Breast Cancer?
Dana-Farber Cancer Institute
Researchers from Dana-Farber Cancer Institute and Brigham and Women's Hospital have received a $10 million Breakthrough Award from the Department of Defense's Office of the Congressionally Directed Medical Research Program to test whether aspirin helps women with breast cancer avoid recurrence and live longer. This is the first ever randomized trial in the United States testing aspirin in the disease. more...
Immunotherapy Researcher Awarded $6.8 Million Grant
Hollings Cancer Center
Zihai Li, MD, PhD, has been awarded a five-year NIH-funded P01 grant totaling nearly $6.8 million. The grant supports multi-institution research on endoplasmic reticulum chaperones in cancer. Dr. Li will serve as overall principal investigator for the grant and leader of the two components based at the Medical University of South Carolina's Hollings Cancer Center. The other two projects will be led by chemical biologist and medicinal chemist Gabriela Chiosis, PhD, at Memorial Sloan-Kettering Cancer Center and structural biologist Daniel Gewirth, PhD, at Hauptman-Woodward Medical Research Institute in Buffalo, New York. more...
Center for Asian Health Equity Awarded $3.5 Million CDC grant
The University of Chicago Medicine Comprehensive Cancer Center
The Center for Asian Health Equity, a partnership between the University of Chicago Medicine and the Asian Health Coalition, has received a five-year, $3.5 million federal grant from the Centers for Disease Control and Prevention to increase colorectal cancer screenings, particularly among underserved communities in Cook County. more...
Press On Gives $2.5 Million to Fund Pediatric Cancer Research, Treatment
GRU Cancer Center
Press On, a donor-advised fund of The Community Foundation for the CSRA, which is pushing for a cure for childhood cancer, is giving $2.5 million to fund translational pediatric cancer research and cutting-edge treatment alternatives at the GRU Cancer Center. The gift will fund the development of the Press On Translational Pediatric Oncology Program at the GRU Cancer Center to boost the discovery and deployment of new treatment alternatives for childhood cancers. more...
Grant Awarded to Develop Clinical Trial to Test New AML Therapy
VCU Massey Cancer Center
VCU Massey Cancer Center researcher Steven Grant, MD, was awarded nearly $1 million in grant funding from the National Center for Advancing Translational Sciences to support the development of a clinical trial that will test a novel, experimental therapy for acute myeloid leukemia that he co-discovered. more...
Exploring Use of Aspirin and a Diabetes Drug for Prostate Cancer Prevention, Control
Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey population science researcher XiangLin Tan, MD, PhD, has been awarded an $852,705 Career Development Award from the National Cancer Institute to explore the use of aspirin and a diabetes drug for prostate cancer prevention and control, especially in obese men. more...
Leadership Transitions
Schulam Serving as Yale Interim Director
Yale Cancer Center
Peter Schulam, MD, PhD, professor of urology and chair/chief of Yale's Department of Urology, is serving as the interim director of Yale Cancer Center and physician-in-chief at Smilow Cancer Hospital at Yale-New Haven. Thomas J. Lynch Jr., MD, who was director of Yale Cancer Center and physician-in-chief of Smilow since 2009, left Yale in August to become chairman and chief executive officer of the Massachusetts General Physicians Organization. more...
Bustamante Named Chair of New Department of Biomedical Data Science
Stanford Cancer Institute
Carlos Bustamante, PhD, founding director of the Stanford Center for Computational, Evolutionary and Human Genomics, has been appointed chair of the new Department of Biomedical Data Science. The department will build on the School of Medicine's strengths in using information technology to advance precision health and work to find common solutions to the challenges of analyzing biomedical data from varied sources, including biosensors, electronic medical records and genomic sequencing. more...
Faculty Appointed to Pathology Leadership Positions
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital & Solove Research Institute

The Ohio State University has recruited two prominent pathologists to serve in leadership roles for specialized pathology services offered across The Ohio State University Wexner Medical Center. Dan Jones, MD, PhD, serves as vice chair and director of molecular pathology in The Ohio State University College of Medicine Department of Pathology. Anil Parwani, MD, PhD, MBA has been appointed vice chair and director of anatomic pathology at The Ohio State University College of Medicine Department of Pathology. more...
Demmy Arrival Enhances Lung Cancer Focus
Rutgers Cancer Institute of New Jersey
Aiming to enrich its focus on lung and other cancers of the chest, Rutgers Cancer Institute of New Jersey is welcoming Todd Demmy, MD, FACS, FCCP, as its new Chief of Thoracic Oncology and Associate Chief of the Division of Surgical Oncology. Dr. Demmy, who is leading Rutgers Cancer Institute's Thoracic Oncology Program, is an international leader in minimally-invasive thoracic surgery and one of the pioneers of video-assisted thoracoscopic surgery. more...
Brunzell Named Program Leader of Cancer Prevention and Control
VCU Massey Cancer Center
Darlene Brunzell, PhD, has been appointed the co-leader of the Cancer Prevention and Control research program at VCU Massey Cancer Center. She will serve in this capacity alongside Jennifer Elston Lafata, PhD, who has co-led the program since 2010. more...
Research Highlights
Poor Survival in Multiple Myeloma Patients Linked to Genetic Variation
Huntsman Cancer Institute
As part of a multi-institutional effort, researchers with Huntsman Cancer Institute at the University of Utah have found that multiple myeloma patients with a genetic variation in the gene FOPNL die on average 1-3 years sooner than patients without it. Nicola Camp, PhD, led the study for Huntsman together with Elad Ziv, MD, at the University of California, San Francisco (UCSF), Celine Vachon, PhD, at the Mayo College of Medicine Rochester and Federico Canzian, PhD, from the German Cancer Research Center. more...
Cell Signal Whets Appetites for Tumor-Devouring Dendritic Cells
The University of Chicago Medicine Comprehensive Cancer Center
Researchers based at the University of Chicago report that using mice with an intact immune system provides a much more lifelike way to study and develop an immune-based cancer therapy than the current model. The study also suggests ways to improve the relative timing of the combination of anti-CD47 antibodies and chemotherapy. Study director was Yang-Xin Fu, MD, PhD. more...
Research Shows Social Factors May Affect Younger Leukemia Patients' Survival
UAB Comprehensive Cancer Center
A University of Alabama at Birmingham study reveals that insurance status, marital status and county-level income may affect the chances of survival in young patients with acute myeloid leukemia. The findings indicate that additional efforts and resources are needed to address the social factors that impact critical aspects of health in these patients. more...
Plant Extract From Traditional Indian Medicine May Fight Blood Cancer
UK Markey Cancer Center
A University of Kentucky study shows that withaferin A, a component of Withania somnifera (winter cherry) plant extract, may hold promise as a new treatment for non-Hodgkin's lymphoma. Winter cherry extract was used in traditional Ayurvedic Indian medicine for thousands of years before it caught the interest of Subbarao Bondada, PhD, a University of Kentucky College of Medicine professor and researcher for the UK Markey Cancer Center. Because withaferin A shows promise in treating other cancers without the side effects associated with current treatments, Dr. Bondada's laboratory tested it against lymphoma. more...
Cell-Surface Discovery Could Lead to Major Breakthrough in Cancer Treatment
University of Virginia Cancer Center
University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease. By more selectively targeting cancer cells, this method offers a strategy to reduce the length of and physical toll associated with current treatments. more...
Discovery Marks Milestone in Understanding Treatment-Resistant Melanoma
Jonsson Comprehensive Cancer Center, UCLA
A new three-year study led by Roger Lo, MD, PhD, could mark a milestone in the quest to track how cancer changes in response to a powerful drug. The findings, Lo said, could lead to methods that would enable early detection of drug-resistant tumor cells and to new therapies designed to suppress resistance as soon as therapy begins. Collaborating with physicians from Vanderbilt-Ingram Cancer Center, Dr. Lo studied drug resistance by analyzing samples of patients’ melanoma tumors both before they underwent therapy and when the disease recurred. more...
Generational Gap Seen in Smoking Cessation in Northern Appalachia
Roswell Park Cancer Institute
Significant differences in attitudes toward smoking cessation are reported between two generations of smokers in Northern Appalachia in new research from Roswell Park Cancer Institute. The qualitative study about beliefs, attitudes and experiences of current and former smokers in Northern Appalachian communities, published in the Journal of Community Health, contributes novel information about smoking cessation. Elisa Rodriguez, PhD, was lead author of the study. more...
Building Human Breast Tissue, Cell by Cell
UCSF Helen Diller Family Comprehensive Cancer Center
The next frontier in developing therapies for cancer and other diseases could come through studying organ development or tumor growth in living humans. Problem is, there's no ethical way of doing that using current technology. Zev Gartner, PhD, has focused on the next best thing: His lab is building fully functioning 3-D human tissue, cell by cell. It sounds straight out of a Frankenstein novel, but Dr. Gartner is working to grow the milk-producing tissues of the human breast to create a living, working model of the human mammary gland that grows, ages and responds to hormone signals just like the real thing. more...
Vaccine for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study
Roswell Park Cancer Institute
An innovative vaccine therapy developed at Roswell Park Cancer Institute is being tested in a multisite clinical trial involving 50 patients with newly diagnosed glioblastoma brain tumors. The phase II study, now accruing patients at both Roswell Park and the Cleveland Clinic, will assess the effectiveness of the SurVaxM vaccine in combination with standard chemotherapy as treatment for this often-fatal cancer. The vaccine, developed by Roswell Park faculty members Robert Fenstermaker, MD, and Michael Ciesielski, PhD, targets survivin, a cell-survival protein that's present in the vast majority of cancers, including glioblastoma. more...
Clinical Trial Shows Promise of "Basket Studies" for Cancer Drugs
Memorial Sloan Kettering Cancer Center
A landmark study led by Memorial Sloan Kettering researchers has demonstrated the potential of precision medicine in cancer treatment. Results of an international clinical trial, published in the New England Journal of Medicine, show that a drug focused on a single genetic mutation can be effective across multiple cancer types — although blocking the mutation does not guarantee success. more...
Cancer Treatment Developed at UK Approved for Clinical Trials
UK Markey Cancer Center
An investigational medical device for the treatment of late stage lung cancer, pioneered by researchers at University of Kentucky, has been approved for clinical trials by the Food and Drug Administration (FDA). UK is the only site in the country approved to test this new treatment on advanced lung cancer patients. The Exatherm Total Body Hyperthermia System (Exatherm-TBH) was developed at UK in a public-private partnership with Exatherm Inc. The project is supported by grant funding from the National Institutes of Health. more...
Genetic Testing All Women for Breast Cancer Might not be Worth the Cost
Jonsson Comprehensive Cancer Center, UCLA
Women who are carriers of mutated BRCA genes are known to have a significantly higher risk for developing breast and ovarian cancers than those who don't. But a new study by UCLA faculty questions the value of screening for the genetic mutations in the general population-including those who do not have cancer or have no family history of the disease-because of the high cost. The paper was authored by Patricia Ganz, MD. more...
Big Data Tool to Reveal Immune System Role in Diseases
Mount Sinai Health System Tisch Cancer Institute
Researchers from the Icahn School of Medicine at Mount Sinai and Princeton University have designed a new online tool that predicts the role of key proteins and genes in diseases of the human immune system. Called "ImmuNet", the tool uses information compiled from 38,088 public experiments to predict new immune pathway interactions, mechanisms, and disease-associated genes. more...
Pancreatic Cancer Subtypes Found in Largest Gene Expression Analysis of the Disease
UNC Lineberger Comprehensive Cancer Center
Dense surrounding tissue can block drugs from reaching pancreatic cancer tumors, but it can also help prevent the cancer from spreading. Now a new study by UNC Lineberger Comprehensive Cancer Center researchers and collaborators helps explain the conflicting role of the surrounding tissue known as stroma. In the study, the researchers revealed that based on molecular characteristics, there are two subtypes of pancreatic cancer stroma. more...
Scientists Discover that an Anti-Inflammatory Drug Acts Against Ovarian Cancer
University of New Mexico Cancer Center
Research from a UNM Comprehensive Cancer Center team, led by Angela Wandinger-Ness, PhD, Laurie Hudson, PhD, and Carolyn Muller, MD, FACOG, has found a novel activity of a post-operative pain medication. The team tested the equal mixture of R- and S-ketorolac in women with ovarian cancer. Ketorolac, marketed as Toradol®, is approved for clinical use in the United States for pain after surgery and is given as a racemic mixture. The research demonstrated that when ketorolac is injected into the bloodstream, the body removes S-ketorolac more rapidly and allows R-ketorolac to move to and gather in the peritoneal cavity. more...
Two-Drug Combination Shows Promise Against One Type of Pancreatic Cancer
UF Health Cancer Center
One form of pancreatic cancer has a new enemy: a two-drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models. For the first time, researchers have shown that a certain protein becomes overabundant in pancreatic neuroendocrine tumors, allowing them to thrive. They also found that pairing a synthetic compound with an existing drug provides a more effective anticancer punch than a single drug. more...
Combining Epigenetic Therapies With Immunotherapies Likely to Improve Outcomes
American Association for Cancer Research (AACR)
Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs, according to a review published in Clinical Cancer Research, a journal of the American Association for Cancer Research. more...
Other News
Sixteen Top Scientists, Educators Announce U.S. Biomedical Research Collaboration
Huntsman Cancer Institute
A diverse team of 16 prominent scientists and educators announced the launch of a high-profile collaboration that seeks to leverage knowledge from the scientific community to confront the dangers to the U.S. biomedical science enterprise. Named Rescuing Biomedical Research, the effort tackles the problems identified in several public statements that the team and the scientific community have made, and aims to take the next steps towards making substantive, concerted changes in the way U.S. biomedical research is conducted and in the way careers are developed. more...
Groundbreaking Set for Additional Kimmel Cancer Center Building
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins Kimmel Cancer Center has broken ground on a new $100 million, 184,000-square-foot cancer care building at one of the highest elevations in East Baltimore. Slated to open in late 2017, the building is named for Albert P. "Skip" Viragh Jr., a Maryland mutual fund investment leader, philanthropist and pancreatic cancer patient treated at Johns Hopkins who died of the disease in 2003 at age 62. more...
SCIEX Partners with Fred Hutch for Targeted Proteomics
Fred Hutchinson Cancer Research Center
SCIEX, a global leader in life science analytical technologies, announced a collaboration with the laboratory of Amanda Paulovich, MD, PhD, at Fred Hutchinson Cancer Research Center, to make Targeted Proteomics in cancer research more reproducible and specific. The collaboration provides SCIEX rights to commercialize the immuno-MRM assays that have been developed in the Paulovich Laboratory, a member of the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium. more...
Job Opportunities
Executive Director for Administration  
Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center

more...

Director of Operations  
Mayo Clinic Cancer Center

more...

Administrative Director, GRU Cancer Center Outpatient Facilities  
Georgia Regents University Cancer Center

more...

Director, Cancer Center Clinical Trials Office   
Georgia Regents University Cancer Center

more...

Chief Financial Officer  
Georgia Regents University Cancer Center

more...

Cancer Center Director- Hematologist/Medical Oncologist  
Bellevue Hospital Center
Perlmutter Cancer Center Director at NYU Langone Medical Center

more...

MGR - Service Center Operations - Cancer Center  
Stanford Cancer Institute

more...

Meeting Announcements

2015 AACI/CCAF Annual Meeting

Register now: aaci-cancer.org/annual_meeting
October 25-27, 2015
Mandarin Oriental, Washington, DC

3rd Annual AACI Physician Clinical Leadership Initiative Meeting

Register now: aaci-cancer.org/pcli_meeting
October 25, 2015
4:00pm-6:00pm EST
Mandarin Oriental, Washington, DC

2016 Capitol Hill Day

AACI will co-host its annual Capitol Hill Day with the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).
May 11-12, 2016
Washington, DC

8th Annual AACI Clinical Research Initiative Meeting

Save the Date!
July 20-21, 2016
Loews Chicago O'Hare Hotel